# EDGAR Filing Document

**Accession Number:** 0001930479
**File Stem:** 0001209191-23-015861
**Filing Date:** 2023-3
**Character Count:** 6294
**Document Hash:** 3cdc91f2ae7178a5c66066e4d4ac2cd6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-015861.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0001209191-23-015861

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230301

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** DeSimone Jill
- **CENTRAL INDEX KEY:** 0001930479

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39743
- **FILM NUMBER:** 23706303

**MAIL ADDRESS:**
- **STREET 1:** C/O PRAXIS PRECISION MEDICINES, INC.
- **STREET 2:** 99 HIGH STREET, 30TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kinnate Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001797768
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 824566526
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 11975 EL CAMINO REAL, STE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 8582994699

**MAIL ADDRESS:**
- **STREET 1:** 11975 EL CAMINO REAL, STE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

## Ex-24

```
<PRE>
             Exhibit 24
		LIMITED POWER OF ATTORNEY FOR
             	SECTION 16 REPORTING OBLIGATIONS
             	The undersigned, as a Section 16 reporting person of Kinnate
Biopharma Inc. (the "Company"), hereby constitutes and appoints Nima Farzan,
Mark Meltz, James Reilly, and Lance Brady as the true and lawful
attorneys-in-fact of the undersigned to:
             1.	complete and execute Forms 3, 4 and 5 and other forms and all
amendments thereto as such attorneys-in-fact shall in their discretion determine
to be required or advisable pursuant to Section 16 of the Securities Exchange
Act of 1934 (as amended) and the rules and regulations promulgated thereunder,
or any successor laws and regulations, as a consequence of the ownership,
acquisition or disposition of securities of the Company by the undersigned; and
             2.	do all acts necessary in order to file such forms with the
Securities and Exchange Commission, any securities exchange or national
association, the Company and such other person or agency as the
attorneys-in-fact shall deem appropriate.
             The undersigned hereby ratifies and confirms all that said
attorneys in-fact and agent shall do or cause to be done by virtue hereof.  The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, is not assuming, nor is the
Company assuming, any of the responsibilities of the undersigned to comply with
Section 16 of the Securities Exchange Act of 1934 (as amended).
             This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4 and 5 with respect to
the holdings of and transactions in securities issued by the Company of the
undersigned, unless earlier revoked by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in-fact.
             IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of the date set forth below.

             By: /s/ Jill DeSimone
             Name: Jill DeSimone
             Date: February 6, 2023

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>DeSimone Jill<br><sub>(Last) (First) (Middle)</sub><br>103 MONTGOMERY STREET, SUITE 150<br>THE PRESIDIO OF SAN FRANCISCO<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94129<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Kinnate Biopharma Inc. [ KNTE ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Signature:** /s/ Mark A. Meltz, attorney-in-fact  
**Date:** 2023-03-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**